HIG1 hypoxia inducible domain family member 1AGenealiases: HIG1 · RCF1a
Q-omics provides the consensus-scored HIGD1A profile across patient tissues and cancer cell-line models. HIGD1A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, HIGD1A is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, HIGD1A protein abundance shows 20,567 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight COAD, KIRC, and GBM as cancer lineages where HIGD1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HIGD1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HIGD1A survival associations across molecular data types. HIGD1A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HIGD1A RNA expression–survival associations across cancer types. High HIGD1A expression shows unfavorable associations in ESCA, ACC, LAML and STAD, but favorable associations in COAD and KIRP. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for HIGD1A RNA expression.
This table summarizes HIGD1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HIGD1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HIGD1A shows lower tumor expression in KIRC, HNSC, COAD, THCA, READ and LUAD. The KIRC box plot shows higher HIGD1A RNA expression in normal versus tumor tissue (log2 FC = −1.703, t-test p < 0.001).
This table shows molecular features associated with HIGD1A in patient tissues and cancer cell lines. In patient samples, HIGD1A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HIGD1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
